Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye
Awwad S, Day RM, Khaw PT, Brocchini S, Fadda HM.
Electrospun formulations of acyclovir, ciprofloxacin and cyanocobalamin for ocular drug delivery
Baskakova A, Awwad S, Jiménez JQ, et al.
The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development
Awwad S, Lockwood A, Brocchini S, Khaw PT.
Antibody loaded collapsible hyaluronic acid hydrogels for intraocular delivery
Egbu R, Brocchini S, Khaw PT, Awwad S.
full publication list
Comparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels
Awwad S, Al-Shohani A, Khaw PT, Brocchini S.
PREVIOUS
TALKS
S. Awwad at Institute of Ophthalmology Symposium, London, U.K.
Development of novel ocular therapies with the PK-Eye model
​
B. Butler at ISOPT, Tel Aviv, Israel
The PK-Eye™: Accelerate the development of drugs for the back of the eye
2018
S. Awwad at SDDS, Prague, Czech Republic
A sustained release intravitreal protein formulation
S. Awwad at EuroPPS, Valencia, Spain
The PK-Eye: the need for an ocular flow model for the development of new therapies
S. Awwad at Global Ophthalmology Summit, London, U.K.
A new model for developing intravitreal formulations
2017
B. Butler at ISOPT, Rome, Italy
Introduction: The PK-Eye™, a new tool for Drug Development
S. Awwad, P. T. Khaw and S. Brocchini at Pharmaceutica, Madrid, Spain
The PK-Eye: A novel in vitro model to evaluate ocular pharmacokinetics
2016
S. Awwad, P. T. Khaw and S. Brocchini at KTN meeting, Cambridge, UK
Extending the therapeutic tail of proteins
S. Awwad, P. T. Khaw and S. Brocchini at UCL, School of Pharmacy Research Day, London, UK
The PK-Eye: why we need an ocular flow model for the development of new therapies